Jerry, you and all of us longs know that the PFS endpoint is being re-evaluated due to pseudo progression caused by DCVaxL itself, which was not fully understood at the start of this trial. Adjudication might well turn up some misdiagnosed progression, which will be corrected before they release PFS data. And before you counter with FDA won’t let this happen, we all know the regulators are quite aware of pseudo progression in immunotherapy.